Outcome of corticosteroid administration in autoimmune pulmonary alveolar proteinosis: a retrospective cohort study
Authors:
- Keiichi AkasakaKAKeiichi Akasaka
- Takahiro TanakaTTTakahiro Tanaka
- Nobutaka KitamuraNKNobutaka Kitamura
- Shinya OhkouchiSOShinya Ohkouchi
- Ryushi TazawaRTRyushi Tazawa
- Toshinori TakadaTTToshinori Takada
- Toshio IchiwataTIToshio Ichiwata
- Etsuro YamaguchiEYEtsuro Yamaguchi
- Masaki HiroseMHMasaki Hirose
- Toru AraiTAToru Arai
- Kentaro NakanoKNKentaro Nakano
- Takahito NeiTNTakahito Nei
Open Access
- 12 August 2015
- journal article
- research article
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 15 (1) , 1-9
Abstract
Although no report has demonstrated the efficacy of corticosteroid therapy for autoimmune pulmonary alveolar proteinosis (aPAP), we sometimes encounter patients who have received this therapy for various reasons. However, as corticosteroids can suppress alveolar macrophage function, corticosteroid therapy might worsen disease severity and increase the risk of infections. For this retrospective cohort study, we sent a screening form to 165 institutions asking for information on aPAP patients treated with corticosteroids. Of the resulting 45 patients screened, 31 were enrolled in this study. We collected demographic data and information about corticosteroid treatment period, dose, disease severity score (DSS) over the treatment period, and complications. DSS deteriorated during corticosteroid therapy in 23 cases (74.1 %) and the estimated overall cumulative worsening rate was 80.8 % for the total observation period. The worsening rate was significantly higher in patients treated with high-dose prednisolone (>18.9 mg/day, n = 16) than treated with low-dose prednisolone (≤18.9 mg/day, n = 15) divided by median daily dose (p < 0.02). Of patients with worsening, one died of disseminated aspergillosis and another of respiratory failure. Infections newly emerged in 6 cases during corticosteroid therapy (p < 0.05). Median serum granulocyte/macrophage colony-stimulating factor (GM-CSF) autoantibody levels were similar to previously reported data in a large cohort study. The results demonstrate that corticosteroid therapy may worsen DSS of aPAP, increasing the risk for infections.Keywords
This publication has 40 references indexed in Scilit:
- Long-term follow-up and treatment of congenital alveolar proteinosisBMC Pediatrics, 2011
- Clinical features of secondary pulmonary alveolar proteinosis: pre-mortem cases in JapanEuropean Respiratory Journal, 2011
- Inhaled Granulocyte/Macrophage–Colony Stimulating Factor as Therapy for Pulmonary Alveolar ProteinosisAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Rituximab therapy in autoimmune pulmonary alveolar proteinosisEuropean Respiratory Journal, 2009
- Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA Journal of Experimental Medicine, 2008
- Characteristics of a Large Cohort of Patients with Autoimmune Pulmonary Alveolar Proteinosis in JapanAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Steroids, surfactant and lung disease.Thorax, 1996
- Involvement of Granulocyte-Macrophage Colony-Stimulating Factor in Pulmonary HomeostasisScience, 1994
- Alveolar proteinosis: diagnosis and treatment over a 10-year period.Thorax, 1983
- Pulmonary alveolar proteinosisRespiratory Medicine, 1969